Memorial Sloan Kettering Cancer Center

A Phase II Study of Sorafenib plus Doxorubicin in Patients with Liver Cancer that Continued Growing with Sorafenib Therapy

Protocol

12-259

Full Title

Phase II Study of Sorafenib plus Doxorubicin in Patients with Advanced Hepatocellular Carcinoma with Disease Progression on Sorafenib

Phase

II

Purpose

Sorafenib is a drug used to treat hepatocellular carcinoma (liver cancer). However, in some patients, the liver cancer continues to grow after having an initial response to sorafenib. There is some evidence that adding the drug doxorubicin to sorafenib therapy may be beneficial for patients with liver cancer, when given as additional treatment after the cancer has grown despite sorafenib.

The purpose of this study is to evaluate the safety and effectiveness of therapy with sorafenib plus doxorubicin in patients with hepatocellular carcinoma that continued to grow despite sorafenib alone. Doxorubicin is an established chemotherapy drug used to treat many types of cancer. Sorafenib is taken orally (by mouth), while doxorubicin is given intravenously (by vein).

Eligibility

To be eligible for this study, patients must meet several criteria, including but not limited to the following:

- Patients must have advanced hepatocellular carcinoma that continued to grow despite prior treatment with sorafenib.
- At least 4 weeks must have passed since any prior local therapy for liver cancer (such as chemoembolization) and 2 weeks since surgery or radiation therapy and entry into the study.
- This study is open to patients age 18 and older.

For more information and to inquire about eligibility for this study, please contact Dr. Ghassan Abou-Alfa at 646-888-4184.

Disease(s)

Hepatobiliary: Liver Cancer

Locations

Memorial Hospital

ClinicalTrials.gov

Visit **ClinicalTrials.gov** for full clinical trial description

Related Diseases

Liver Cancer

©2014 Memorial Sloan Kettering Cancer Center
Source URL (retrieved on *09/23/2014 - 6:26 PM*): http://www.mskcc.org/cancer-care/trial/12-259